Bristol Myers Squibb Company $BMY Shares Bought by New York State Teachers Retirement System

New York State Teachers Retirement System grew its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 0.9% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 1,838,597 shares of the biopharmaceutical company’s stock after buying an additional 16,839 shares during the period. New York State Teachers Retirement System’s holdings in Bristol Myers Squibb were worth $82,921,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Trifecta Capital Advisors LLC acquired a new position in Bristol Myers Squibb in the second quarter valued at about $25,000. Darwin Wealth Management LLC purchased a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at approximately $25,000. Harbor Capital Advisors Inc. lifted its holdings in shares of Bristol Myers Squibb by 107.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 313 shares during the last quarter. REAP Financial Group LLC lifted its holdings in shares of Bristol Myers Squibb by 202.8% in the 2nd quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 428 shares during the last quarter. Finally, DHJJ Financial Advisors Ltd. increased its holdings in Bristol Myers Squibb by 51.9% in the 2nd quarter. DHJJ Financial Advisors Ltd. now owns 781 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 267 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: UBS upgraded BMY, citing improved fundamentals and/or valuation support from recent earnings and guidance — a boost for investor confidence and likely a contributor to buying interest. Bristol Myers Squibb (NYSE:BMY) Stock Rating Upgraded by UBS Group
• Positive Sentiment: Piper Sandler reiterated a buy rating for BMY, reinforcing sell‑side support and reducing downside risk from analyst sentiment. Piper Sandler Sticks to Their Buy Rating for Bristol-Myers Squibb (BMY)
• Positive Sentiment: BioNTech and Bristol Myers Squibb expanded a pancreatic cancer program with a new Phase II trial — clinical progress in a high‑need oncology indication improves long‑term upside potential if data are positive. BioNTech and Bristol-Myers Squibb Push Deeper Into Pancreatic Cancer With New Phase II Trial
• Positive Sentiment: BMY added a new immunotherapy combo in small‑cell lung cancer, broadening its oncology pipeline and potential label-expansion or combination opportunities. Pipeline depth tends to support premium multiples in pharma names. Bristol Myers Squibb Adds New Immunotherapy Combo Bet in Small Cell Lung Cancer
• Neutral Sentiment: Analyst/industry pieces (Argus, Yahoo valuation reviews, and a Zacks recap) note BMY’s recent share gains and evolving profitability story but raise valuation questions as shares have recovered — these provide context but no immediate directional trigger. Assessing Bristol Myers Squibb (BMY) Valuation As Shares Gain And Profitability Narrative Evolves
• Neutral Sentiment: CNBC preview of the JPMorgan Healthcare Conference highlights that the event could be a catalyst (pipeline updates, commercialization and M&A talk) for BMY, but outcomes depend on what management and peers announce. Healthy Returns: What to expect from pharma at the JPM conference
• Neutral Sentiment: Headline pieces summarizing recent developments (Yahoo/TipRanks recaps) provide useful investor reading but are largely descriptive rather than delivering a single market-moving event. How Recent Developments Are Shaping The Bristol Myers Squibb (BMY) Investment Story

Analyst Ratings Changes

A number of research firms have commented on BMY. Truist Financial set a $65.00 price target on Bristol Myers Squibb in a research note on Wednesday, December 3rd. Wells Fargo & Company increased their price target on shares of Bristol Myers Squibb from $53.00 to $55.00 and gave the stock an “equal weight” rating in a research report on Wednesday, December 10th. UBS Group upgraded Bristol Myers Squibb from a “neutral” rating to a “buy” rating and lifted their target price for the company from $46.00 to $65.00 in a report on Wednesday. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Finally, Morgan Stanley reissued an “underweight” rating and set a $37.00 target price (up previously from $36.00) on shares of Bristol Myers Squibb in a research report on Friday, December 12th. Six research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $56.62.

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY opened at $55.92 on Friday. The stock has a market capitalization of $113.84 billion, a price-to-earnings ratio of 18.89, a PEG ratio of 9.29 and a beta of 0.29. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $63.33. The company has a 50-day simple moving average of $50.93 and a 200-day simple moving average of $47.80. The company has a debt-to-equity ratio of 2.39, a quick ratio of 1.17 and a current ratio of 1.27.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, topping analysts’ consensus estimates of $1.52 by $0.11. The company had revenue of $12.22 billion during the quarter, compared to analysts’ expectations of $11.75 billion. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The firm’s revenue for the quarter was up 2.8% on a year-over-year basis. During the same period last year, the firm earned $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. On average, analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd will be paid a $0.63 dividend. The ex-dividend date of this dividend is Friday, January 2nd. This represents a $2.52 annualized dividend and a yield of 4.5%. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio is presently 85.14%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.